

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
20 July 2006 (20.07.2006)

PCT

(10) International Publication Number  
**WO 2006/074964 A1**

## (51) International Patent Classification:

C07K 7/06 (2006.01) C07K 14/705 (2006.01)  
C07K 7/64 (2006.01) C07K 7/56 (2006.01)  
C07K 14/47 (2006.01)

(74) Agent: BOHMANN, Armin, K.; Bohmann & Loosen,  
Sonnenstrasse 8, 80331 Munich (DE).

## (21) International Application Number:

PCT/EP2006/000365

(22) International Filing Date: 17 January 2006 (17.01.2006)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

05000857.2 17 January 2005 (17.01.2005) EP

(71) Applicant (for all designated States except US): JERINI  
AG; Invalidenstr. 130, 10115 Berlin (DE).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): HUMMEL, Gerd  
[DE/DE]; Pankstr. 12, 13357 Berlin (DE). LOCARDI,  
Elsa [DE/DE]; Rigaer Strasse 56, 10247 Berlin (DE).  
POLAKOWSKI, Thomas [DE/DE]; Dünckerstrasse 29a,  
10439 Berlin (DE). SCHARN, Dirk [DE/DE]; Berliner  
Strasse 95, 13507 Berlin (DE). SCHNATBAUM, Karsten  
[DE/DE]; Seumestrass 8, 10245 Berlin (DE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,  
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: C5A RECEPTOR ANTAGONISTS



(57) Abstract: The present invention is related to  
a compound, preferably a C5a receptor antagonist,  
having the following structure: (I), whereby X1 is a  
radical having a mass of about 1-300, whereby X1 is  
preferably selected from the group comprising R5-,  
R5-CO-, R5-N(R6)-CO-, R5-O-CO-, R5-SO<sub>2</sub>-,  
R5-N(R6)-SO<sub>2</sub>-, R5-N(R6)-, R5-N(R6)-CS-,  
R5-N(R6)-C(NH)-, R5-CS-, R5-P(O)OH-5  
R5-B(OH)-, and R5 -CH=N-O-CH<sub>2</sub>-CO-, whereby

R5 and R6 are individually and independently selected from the group comprising H, F, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, alkoxy, alkoxyalkyl, substituted alkoxyalkyl, aryloxyalkyl and substituted aryloxyalkyl, X2 is a radical that mimics the biological binding characteristics of a phenylalanine unit, X3 and X4 are individually and independently a spacer, whereby the spacer is preferably selected from the group comprising amino acids, amino acid analogs and amino acid derivatives, X5 is a radical that mimics the biological binding characteristics of a cyclohexylalanine or homoleucine unit, X6 is a radical that mimics the biological binding characteristics of a tryptophane unit, X7 is a radical that mimics the biological binding characteristics of a norleucine or phenylalanine unit, a chemical bond X3 and X7 is formed, and the connecting lines - in formula (I) indicate chemical bonds, whereby the chemical bond is individually and independently selected from the group comprising covalent bonds, ionic bonds and coordinative bonds, whereby preferably the bond is a chemical bond and more preferably the chemical bond is a bond selected from the group comprising amide bonds, disulfide bonds, ether bonds, thioether bonds, oxime bonds and aminotriazine bonds, whereby the compound is in particular useful for the manufacture of a medicament for the treatment of autoimmune diseases.

WO 2006/074964 A1